Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial.
2型糖尿病中慢性腎病嚴重程度對semaglutide心血管結果的影響:FLOW試驗。
Eur Heart J 2024-08-30
Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial.
SUSTAIN 6 試驗中,按 KDIGO 風險類別劑量每週一次的 Semaglutide 對腎病結果的影響。
Kidney Int Rep 2024-07-31
Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6.
Semaglutide對SUSTAIN 6和PIONEER 6中不同基線HbA1c、血壓、體重和白蛋白尿水平的腎功能影響。
Nephrol Dial Transplant 2024-07-02
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.
Semaglutide在肥胖和心血管疾病中的SELECT試驗中的長期腎臨床結果。
Nat Med 2024-05-25
Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study.
慢性腎臟疾病及其嚴重程度對賽馬魯替胰噴酮在第2型糖尿病患者療效的影響:多中心實務研究。
Front Endocrinol (Lausanne) 2023-11-22
Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis.
Semaglutide對基線腎功能參數不同的2型糖尿病患者及高心血管疾病風險者主要不良心血管事件的影響:SUSTAIN 6和PIONEER 6事後合併分析。
Cardiovasc Diabetol 2023-11-21
Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo.
SUSTAIN 6和PIONEER 6試驗的事後分析表明,高心血管風險的2型糖尿病患者接受semaglutide治療,腎功能比安慰劑更穩定。
Kidney Int 2023-08-30